Introduction: Lanreotide autogel (LAN) and temozolomide (TMZ) are guidelines-recommended monotherapies for thoracic neuroendocrine tumors (carcinoids; T-NETs), but prospective data for both combined and monotherapies are lacking. ATLANT (NCT02698410) evaluated efficacy and safety of LAN/TMZ in progressive T-NETs. Methods: ATLANT was a 12-month, Italian, phase 2, single-arm, open-label, multicenter pilot study. Eligible patients had unresectable, locally advanced/metastatic, well-/moderately differentiated T-NETs with radiological progression. Patients received subcutaneous LAN 120 mg every 28 days and oral TMZ 250 mg/day for 5 consecutive days every 28-day cycle. Main endpoints are disease control rate (DCR) at 9 months (primary; investigator-assessed), median progression-free survival (PFS), biomarkers, and safety. Results: The number of patients was 40; 60% were male. Primary tumor site was lung (90%) and thymus (10%). Carcinoid type was typical (20.0%) and atypical (52.5%). DCR at 9 months was 35.0% (95% confidence interval (CI) 20.63–51.68; nonacceptability threshold ≤10%, p < 0.0001; not significantly above clinically relevant threshold ≥30%, p = 0.2968). DCR between 7.5 and 10.5 months (sensitivity analysis) was 45.0% (95% CI: 29.26–61.51) and clinically relevant (p = 0.0320 at ≥30% threshold). Median PFS was 37.1 (95% CI: 24.1–52.9) weeks. No association was observed between biomarker variations (chromogranin A, neuron-specific enolase, somatostatin receptor type-2, Ki-67, 6-O-methylguanine-DNA-methyl-transferase) and DCR or PFS. Most patients (97.5%) had treatment-emergent adverse events (TEAEs); 72.5% had treatment-related TEAEs. TEAEs were mainly grade 1/2. No unanticipated TEAEs were reported. Conclusions: This study showed that the LAN/TMZ combination has promising efficacy in progressive T-NETs, and was well tolerated. Larger studies are warranted to support the clinical benefits of LAN/TMZ in patients with T-NETs.

1.
Yao
JC
,
Hassan
M
,
Phan
A
,
Dagohoy
C
,
Leary
C
,
Mares
JE
,
.
One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States
.
J Clin Oncol
.
2008 Jun 20
;
26
(
18
):
3063
72
.
2.
Oberg
K
,
Knigge
U
,
Kwekkeboom
D
,
Perren
A
;
ESMO Guidelines Working Group
.
Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
.
Ann Oncol
.
2012 Oct
;
23
(
Suppl 7
):
vii124
130
.
3.
Travis
WD
,
Brambilla
E
,
Burke
AP
,
Marx
A
,
Nicholson
AG
.
WHO Classification of tumours of the lung, pleura, thymus and heart
. 4th ed.
Lyon
:
IARC Press
;
2015
.
4.
Stueven
AK
,
Kayser
A
,
Wetz
C
,
Amthauer
H
,
Wree
A
,
Tacke
F
,
.
Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future
.
Int J Mol Sci
.
2019
;
20
(
12
):
3049
.
5.
Faggiano
A
,
Lo Calzo
F
,
Pizza
G
,
Modica
R
,
Colao
A
.
The safety of available treatments options for neuroendocrine tumors
.
Expert Opin Drug Saf
.
2017 Oct
;
16
(
10
):
1149
61
.
6.
Tsoukalas
N
,
Baxevanos
P
,
Aravantinou-Fatorou
E
,
Tolia
M
,
Galanopoulos
M
,
Tsapakidis
K
,
.
Advances on systemic treatment for lung neuroendocrine neoplasms
.
Ann Transl Med
.
2018
;
6
(
8
):
146
.
7.
Caplin
ME
,
Pavel
M
,
Cwikla
JB
,
Phan
AT
,
Raderer
M
,
Sedlackova
E
,
.
Lanreotide in metastatic enteropancreatic neuroendocrine tumors
.
N Engl J Med
.
2014 Jul
;
371
(
3
):
224
33
.
8.
Vinik
AI
,
Wolin
EM
,
Liyanage
N
,
Gomez-Panzani
E
,
Fisher
GA
.
Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (elect): a randomized, double-blind, placebo-controlled trial
.
Endocr Pract
.
2016 Sep
;
22
(
9
):
1068
80
.
9.
Ipsen Biopharmaceuticals‚ Inc
. Somatuline Depot Prescribing Information.
2021 Feb
. Available from: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/sites/9/2019/06/24155556/Somatuline_Depot_Full_Prescribing_Information.pdf.
10.
Ipsen Ltd
. Somatuline® Autogel® Summary of Product Characteristics.
2020 Jul
. Available from: https://www.medicines.org.uk/emc/product/8257/smpc.
11.
Ferolla
P
,
Brizzi
MP
,
Meyer
T
,
Mansoor
W
,
Mazieres
J
,
Do Cao
C
,
.
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial
.
Lancet Oncol
.
2017 Dec
;
18
(
12
):
1652
64
.
12.
Caplin
ME
,
Baudin
E
,
Ferolla
P
,
Filosso
P
,
Garcia-Yuste
M
,
Lim
E
,
.
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
.
Ann Oncol
.
2015 Aug
;
26
(
8
):
1604
20
.
13.
Pavel
M
,
O’Toole
D
,
Costa
F
,
Capdevila
J
,
Gross
D
,
Kianmanesh
R
,
.
ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site
.
Neuroendocrinology
.
2016
;
103
(
2
):
172
85
.
14.
Baudin
E
,
Caplin
M
,
Garcia-Carbonero
R
,
Fazio
N
,
Ferolla
P
,
Filosso
PL
,
.
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
.
Ann Oncol
.
2021
;
32
(
4
):
439
51
.
15.
Ferolla
P
.
Medical therapy of pulmonary neuroendocrine neoplasms: targeted, symptomatic and chemotherapy
.
Front Horm Res
.
2015
;
44
:
193
7
.
16.
Fazio
N
,
Granberg
D
,
Grossman
A
,
Saletan
S
,
Klimovsky
J
,
Panneerselvam
A
,
.
Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study
.
Chest
.
2013 Apr
;
143
(
4
):
955
62
.
17.
Tesei
A
,
Ricotti
L
,
De Paola
F
,
Casini-Raggi
C
,
Barzanti
F
,
Frassineti
GL
,
.
Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study
.
J Chemother
.
2000 Jan
;
12
(
5
):
421
30
.
18.
Ekeblad
S
,
Sundin
A
,
Janson
ET
,
Welin
S
,
Granberg
D
,
Kindmark
H
,
.
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
.
Clin Cancer Res
.
2007 May 15
;
13
(
10
):
2986
91
.
19.
Crona
J
,
Fanola
I
,
Lindholm
DP
,
Antonodimitrakis
P
,
Öberg
K
,
Eriksson
B
,
.
Effect of temozolomide in patients with metastatic bronchial carcinoids
.
Neuroendocrinology
.
2013
;
98
(
2
):
151
5
.
20.
Pavel
M
,
Denecke
T
,
Lahner
H
,
Hörsch
D
,
Rinke
A
,
Koch
A
,
.
Disease control in progressive pancreatic and intestinal neuroendocrine tumours by combined treatment with lanreotide autogel and temozolomide: the SONNET study
.
15th Annual ENETS conference 2018
.
2018
. abst #2094.
21.
Travis
WD
,
Brambilla
E
,
M Müller-Hermelink
HK
,
Harris
CC
.
WHO classification tumours of the lung, pleura, thymus and heart
.
Lyon, France
:
IARC Press
;
2004
.
22.
Eisenhauer
EA
,
Therasse
P
,
Bogaerts
J
,
Schwartz
LH
,
Sargent
D
,
Ford
R
,
.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
.
Eur J Cancer
.
2009 Jan
;
45
(
2
):
228
47
.
23.
Schmitt
AM
,
Pavel
M
,
Rudolph
T
,
Dawson
H
,
Blank
A
,
Komminoth
P
,
.
Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms
.
Neuroendocrinology
.
2014
;
100
(
1
):
35
44
.
24.
Fazio
N
,
Buzzoni
R
,
Delle Fave
G
,
Tesselaar
ME
,
Wolin
E
,
Van Cutsem
E
,
.
Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis
.
Cancer Sci
.
2018 Jan
;
109
(
1
):
174
81
.
25.
Lv
Y
,
Han
X
,
Zhang
C
,
Fang
Y
,
Pu
N
,
Ji
Y
,
.
Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs
.
Endocr Connect
.
2018
;
7
(
1
):
169
78
.
26.
Pavel
ME
,
Baudin
E
,
Öberg
KE
,
Hainsworth
JD
,
Voi
M
,
Rouyrre
N
,
.
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study
.
Ann Oncol
.
2017 Jul 1
;
28
(
7
):
1569
75
.
27.
Pavel
ME
,
Phan
AT
,
Wolin
EM
,
Mirakhur
B
,
Liyanage
N
,
Pitman Lowenthal
S
,
.
Effect of lanreotide depot/autogel on urinary 5-hydroxyindoleacetic acid and plasma chromogranin A biomarkers in nonfunctional metastatic enteropancreatic neuroendocrine tumors
.
Oncologist
.
2019 Apr
;
24
(
4
):
463
74
.
28.
Koumarianou
A
,
Antoniou
S
,
Kanakis
G
,
Economopoulos
N
,
Rontogianni
D
,
Ntavatzikos
A
,
.
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
.
Endocr Relat Cancer
.
2012 Feb
;
19
(
1
):
L1
4
.
29.
Rindi
G
,
Klersy
C
,
Inzani
F
,
Fellegara
G
,
Ampollini
L
,
Ardizzoni
A
,
.
Grading the neuroendocrine tumors of the lung: an evidence-based proposal
.
Endocr Relat Cancer
.
2014 Feb
;
21
(
1
):
1
16
.
30.
Pelosi
G
,
Rindi
G
,
Travis
WD
,
Papotti
M
.
Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice
.
J Thorac Oncol
.
2014 Mar
;
9
(
3
):
273
84
.
31.
Grozinsky-Glasberg
S
,
Shimon
I
,
Korbonits
M
,
Grossman
.
AB Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms
.
Endocr Relat Cancer
.
2008 Sep
;
15
(
3
):
701
20
.
32.
Neyns
B
,
Tosoni
A
,
Hwu
WJ
,
Reardon
DA
.
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects
.
Cancer
.
2010 Jun 15
;
116
(
12
):
2868
77
.
33.
Hassel
JC
,
Sucker
A
,
Edler
L
,
Kurzen
H
,
Moll
I
,
Stresemann
C
,
.
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
.
Br J Cancer
.
2010
;
103
(
6
):
820
6
.
34.
Kulke
MH
,
Hornick
JL
,
Frauenhoffer
C
,
Hooshmand
S
,
Ryan
DP
,
Enzinger
PC
,
.
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
.
Clin Cancer Res
.
2009
;
15
(
1
):
338
45
.
35.
Ranbaxy Ltd
. Temozolomide. Summary of Product Characteristics, December 2019.
2020 Nov
. Available from: https://www.medicines.org.uk/emc/product/5312/smpc#gref.
36.
Caplin
ME
,
Pavel
M
,
Phan
AT
,
Cwikla
JB
,
Sedlackova
E
,
Thanh
XMT
,
.
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
.
Endocrine
.
2021 Oct 14
;
71
(
2
):
502
13
.
37.
Merck & Co. Inc
. Temozolomide. Prescribing information, February 2016.
2021 Feb
. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021029s031lbl.pdf.
You do not currently have access to this content.